HRT Financial’s NeuroSense Therapeutics NRSN Stock Holding History

HRT Financial’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7K	Buy	+526	New	+$8.2K	﹤0.01%	4014
2025 Q3	–	Sell	-1,085	Closed	-$41K	–	3420
2025 Q2	$41K	Buy	+1,085	New	+$31.4K	﹤0.01%	2331
2025 Q1	–	Sell	-3,220	Closed	-$77K	–	3116
2024 Q4	$77K	Buy	+3,220	New	+$74.1K	﹤0.01%	2067
2024 Q1	–	Sell	-700	Closed	-$10K	–	2836
2023 Q4	$10K	Buy	+700	New	+$9.3K	﹤0.01%	2084

Other funds holding NRSN

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

HRT Financial's NRSN Position: Q2 2026 in Review

HRT Financial opened a new position in NeuroSense Therapeutics (NRSN) in Q2 2026: 526 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #4014 among its holdings. This is a return to the name: HRT Financial previously reported a position in NRSN as recently as Q2 2025.

HRT Financial first reported a position in NRSN in Q4 2023 and has held it in 4 quarters since. The position peaked at $77K in Q4 2024. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

HRT Financial held 526 shares of NeuroSense Therapeutics worth $7K as of Q2 2026.
NeuroSense Therapeutics was a new HRT Financial position in Q2 2026.
NeuroSense Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #4014 holding.
HRT Financial first reported a position in NeuroSense Therapeutics in Q4 2023 and has held it in 4 quarters since.
HRT Financial's NeuroSense Therapeutics position peaked at $77K in Q4 2024.
12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.